Alzheimer's disease is the most common form of dementia, accounting for 60% to 80% of cases according to the World Health Organization (WHO). It involves a deterioration of memory, intellect, behavior and ability to perform daily living activities. This disease has an impact, not only on those who suffer from it, but also families and caregivers who experience great physical, emotional and economic stress.
It is currently estimated that more than 35 million people worldwide suffer from Alzheimer's, a figure that continues to grow. The WHO estimates that by 2030 the number of detected cases more than double.
Grifols and Alzheimer's
Since 2004, we have led a broad range of research initiatives on Alzheimer's.
The AMBAR hypothesis
AMBAR is an innovative clinical trial aimed at slowing down the progression of Alzheimer's disease through periodic therapeutic plasma exchange.
Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.
This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.
Are you a healthcare professional?